ABUS vs MCO · P/E 5.4, rev $6.2M vs P/E 33, rev $7.72B
Arbutus Biopharma Corp (ABUS) versus Moodys Corporation (MCO) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Moodys Corporation (MCO) is a financial data & stock exchanges company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MCO revenue for 2025-12-31 was $7.72B. Net income was $2.46B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. MCO currently screens at market cap $79.69B and trailing P/E 32.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MCO currently screens at market cap $79.69B and trailing P/E 32.7.
Not investment advice. Open the ABUS and MCO stock pages for the full models.
Not investment advice.